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PROBLEM IDENTIFICATION AND DESCRIPTION OF
NEED
The opioid crisis has warranted
nationwide attention towards not only
the current prescribing patterns of
pain medications, but also towards
rehabilitating affected members of
the community. Current interventions
include the use of suboxone
(buprenorphine + naloxone) as well
as Subutex (buprenorphine).

As the implementation of partial
opioid antagonists increase on a
statewide level (1), investigating
factors such as drivers of substance
relapse are worth considering to
further improve adherence to
currently available treatment
regimens.

PROBLEM IDENTIFICATION AND DESCRIPTION OF
NEED
As previously investigated by Kadam et.al., sociodemographic factors such as single
status, unemployment, lower socioeconomic status, and criminal history drove relapse in
individuals with alcohol or opioid dependence. For opioid dependence in particular,
cravings and perceived criticism were also commonly cited as reasons to relapse. (2)

Smyth et.al. noted a 91% reported relapse rate in a study of consecutive opioid
dependent patients admitted to a residential addiction treatment facility. In these
individuals, relapse was noted to have occurred within the first week in 59% of cases. (3)

PUBLIC HEALTH COST AND COST
CONSIDERATIONS
•As mentioned by Florence et.al., the cost of the opioid crisis from a nationwide study
in 2013 was estimated to be $78.5 billion with over a third of this amount due to
increased healthcare and substance abuse treatment costs. (4)

•Opioid partial antagonists such as Suboxone were leaders in both spending and
utilization in the 2018 Vermont State Pharmacy Best Practices and Cost Control
Report. Claims were noted to have increased by 8.3% with Suboxone utilization
increasing by 10%. (1)
•Through the opioid initiatives implemented by the State of Vermont, opioid utilization
decreased by 30% with the number of individual opioid users down 36%. (5)

COMMUNITY PERSPECTIVE
“I think some of the common characteristics of patients that have relapsed are those patients who
are not completely committed to their sobriety, they want to game the system (getting Suboxone
but continuing to use illicit substances), they are not always truthful about what is going on in
their lives or about what substances they used. They deny the use of any illicit substance despite
the evidence of use in their urine screens. These patients are the more difficult patients to work
with in an office setting. I don't think they realize that the only ones they are hurting are
themselves and their families.”
(Barbara Wynes, MAT RN Care Coordinator)

Stress has been a common additional theme amongst patients that tended to relapse, making it
significantly more difficult for patients to adhere to treatment as well as refrain from substance
usage. These stressors often include recent deaths, poverty, and unemployment.
(Summary from interview of Chelsea Poland, MAT Care Coordinator)

INTERVENTION AND METHODOLOGY
This study took place in Swanton, VT, a small town in Franklin County, Vermont at a rural
private family medicine practice. To determine general drivers of relapse in Northwest
Vermont, a small survey was developed in coordination with MAT providers that resided within
this practice. Surveys were provided to all patients in the clinic, however only those that
checked suboxone usage were retained for analysis. This survey was designed for suboxone
users as it was the most commonly prescribed medication within this target demographic. 45
survey respondents along with their responses remained confidential and were not shown to
providers to avoid identification of specific individuals through association. This survey ran for
8 business days between the months of July and August 2019. Specific dates were
intentionally excluded to avoid identification of respondents.

Investigated variables were: duration of treatment, age, current employment status, history of
relapse, reasons for relapse, difficult substances to avoid, and open-ended suggestions. Survey
responses were then tallied and aggregated into appropriate visual formats in a handout
format. This handout was presented to MAT providers to better provide targeted care to
current and future individuals in a suboxone treatment program.

RESULTS/RESPONSES
▪Number of respondents: 45
▪Average length of maintenance treatment: 6.5 years
▪Age distribution: >50 y.o. (11%), <50 y.o. (89%)
▪Overall relapse rate: 53.3%
▪Most common reasons for relapsing: Cravings, Access to Substances, Stress
▪Most difficult substances to avoid during treatment: Prescription Opioids,
Crack/Cocaine, Heroin
▪Most common community suggestion: Would like to be able to speak to someone
unrelated to treatment team about my problems
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EFFECTIVENESS AND LIMITATIONS
Effectiveness:
• The conclusions provided by this study serve to reinforce prior studies in regards to contributors to relapse.
• As the reported relapse rate by the individuals in this study were lower then expected, it may suggest the interventions
provided by the MAT coordinators were effective.
• Continued effort and awareness of the specific struggles unique to this community will be essential towards adapting to
changing substance use patterns over time, especially with the recent rise of stimulant use (crack/cocaine). These tracking
forms provided valuable data regarding existing patterns as well as to how the patient population is evolving.
Limitations:
• As this study was performed in a rural community, the results may not translate into higher population areas and their greater
inherent variability.
• Another limitation is response bias due to stigmatization or misinterpretation of questions due to limited education.
• Those in treatment for a longer duration may also exhibit different characteristics compared to those that paused treatment
post- early relapse.

FUTURE INTERVENTIONS
•Future directions include investigating rates of relapse in relation to suboxone dosing
and tapering.
•As many individuals noted cravings and difficulty refraining from prescription opioid
use as being the top contributors, it may be worth looking into the how tapers affect
end-treatment relapse rates.
•In many cases, tapering a patient off Suboxone continues to be a challenge and their
responses are often unpredictable.

•Quote from anonymous respondent on feedback form:
• “The #1 concern I feel is the greatest threat is getting off suboxone. There don’t seem to be any other
methods than taper. Most people can’t get rid of the last doses.”
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